InvestorsHub Logo
Followers 15
Posts 993
Boards Moderated 0
Alias Born 06/04/2014

Re: None

Thursday, 08/16/2018 9:46:35 PM

Thursday, August 16, 2018 9:46:35 PM

Post# of 1319
Oliceridine NDA remains on track for a November 2, 2018 FDA decision –

– First license agreements for ex-US development and commercialization of oliceridine add potential revenue streams –

– Early pipeline continues to advance –

CHESTERBROOK, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN) today announced financial results for the quarter ended June 30, 2018 and provided an update on its pipeline of differentiated new chemical entities, including its lead asset, oliceridine, currently under review by the U.S. Food and Drug Administration (FDA) for potential approval this year.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TRVN News